Literature DB >> 8152250

Molecular variants of the 1;19 chromosomal translocation in pediatric acute lymphoblastic leukemia (ALL).

E Privitera1, A Luciano, D Ronchetti, M Aricò, T Santostasi, G Basso, A Biondi.   

Abstract

The t(1;19)(q23;p13), a non-random chromosome rearrangement associated with childhood pre-B acute lymphoblastic leukemia (ALL), results at molecular level in the hybrid E2A-PBX1 gene. This gene is expressed in a typical set of fusion transcripts and oncogenic chimeric proteins. However, the occurrence of t(1;19) molecular variants has been recently suggested. In an attempt to identify these variants, we analyzed 25 pediatric cases of pre-B cIg+ cell ALL. We used Southern blot analysis to detect E2A gene rearrangements and RT-PCR to detect chimeric E2A-pbx1 transcripts. In addition to seven cases with the molecular pattern usually associated with the t(1;19), we identified three molecular variants. In one case, a variant E2A-pbx1 transcript showed 27 additional base pairs inserted in frame at the junction site. In two cases, Southern blot evidenced the expected E2A gene rearrangements. However, extensive RT-PCR analysis failed to detect any E2A-pbx1 transcript. These findings led us to hypothesize that a gene other than PBX1 might be involved in these 1;19 variant translocations.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8152250

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  2 in total

1.  An optimized technology platform for the rapid multiplex molecular analysis of genetic alterations associated with leukemia.

Authors:  Fei Ye; Walairat Laosinchai-Wolf; Emmanuel Labourier
Journal:  Cancer Genet       Date:  2012-09-29

2.  Risk-based classification of leukemia by cytogenetic and multiplex molecular methods: results from a multicenter validation study.

Authors:  C D Gocke; J Mason; L Brusca; W Laosinchai-Wolf; C Higgs; H Newell; A Masters; L Friar; J Karp; M Griffiths; Q Wei; E Labourier
Journal:  Blood Cancer J       Date:  2012-07-13       Impact factor: 11.037

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.